WIN-Partners CoTSE:3183 +0.31%63 EBITDA Margin % is 3.70% as of Mar. 2026, which is 14% below its 10-year median of 4.32. GuruFocus rates TSE:3183 with a GF Score™ of 63/100 and a GF Value™ of 円1,522.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, WIN-Partners Co ranks worse than 57.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. WIN-Partners Co's EBITDA for the
six
months ended in Mar. 2026 was 円1,725 Mil. WIN-Partners Co's Revenue for the
six
months ended in Mar. 2026 was 円46,653 Mil. Therefore, WIN-Partners Co's EBITDA margin for the quarter that ended in Mar. 2026 was 3.70%.
WIN-Partners Co (TSE:3183) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
WIN-Partners Co EBITDA Margin % Related Terms
WIN-Partners Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for WIN-Partners Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3183 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, WIN-Partners Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WIN-Partners Co (TSE:3183) has a EBITDA Margin % of 3.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WIN-Partners Co and its competitors. This is 14% below median its historical median of 4.32. Over the past decade, WIN-Partners Co's EBITDA Margin % has ranged from 3.67 to 6.51. According to the industry distribution chart, WIN-Partners Co ranks #67 out of 117 companies in the Medical Distribution industry, placing it in the top 57.3%.
Is WIN-Partners Co's EBITDA Margin % too high?
WIN-Partners Co's current EBITDA Margin % of 3.70% is 14% below median its 10-year median of 4.32. Over the past 10 years, this metric has ranged from a low of 3.67 to a high of 6.51. The Medical Distribution industry median EBITDA Margin % is 4.20. WIN-Partners Co's value of 3.70% is 11.9% below this industry median. Based on the distribution chart, WIN-Partners Co ranks #67 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, WIN-Partners Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, WIN-Partners Co ranks #67 out of 117 companies for EBITDA Margin %. This places WIN-Partners Co in the lower half of its industry. The industry median EBITDA Margin % is 4.20. WIN-Partners Co's value of 3.70% is 11.9% below this benchmark. Historically, WIN-Partners Co's own EBITDA Margin % has ranged from 3.67 to 6.51 over the past decade. While the company's 10-year median is 4.32 vs. the industry median of 4.20, WIN-Partners Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.20, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current EBITDA Margin % of 3.70% is 11.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WIN-Partners Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current EBITDA Margin % is 3.70%, which is 14% below median its own 10-year median of 4.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,522.55, compared to a current price of 円1,285.00 — trading 15.6% below its estimated fair value. The current EBITDA Margin % is 3.70%, which is 14% below median its 10-year median of 4.32 and 11.9% below the Medical Distribution industry median of 4.20. WIN-Partners Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current EBITDA Margin % is 3.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,285.00 is trading 15.6% below its estimated GF Value™ of 円1,522.55.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
EBITDA Margin %: 3.70% (14% below median its 10-year median of 4.32)
GF Value™: 円1,522.55 vs. price of 円1,285.00 (15.6% below fair value)
Industry Position: 11.9% below the Medical Distribution median (#67 of 117)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
63GF Score
Get the complete analysis for TSE:3183
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
